Search
Oculis Holding AG
OCSAdd to Watchlist
30.290USD
+0.070+0.23%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
1.69BMarket Cap
LossP/E TTM
More Details of Oculis Holding AG Company
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
Oculis Holding AG Info
Ticker SymbolOCS
Company nameOculis Holding AG
IPO dateMar 03, 2023
CEOSherif (Riad)
Number of employees49
Security typeOrdinary Share
Fiscal year-endMar 03
AddressBahnhofstrasse 20
CityZUG
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountrySwitzerland
Postal code6300
Phone41417113960
Websitehttps://oculis.com/
Ticker SymbolOCS
IPO dateMar 03, 2023
CEOSherif (Riad)
Company Executives of Oculis Holding AG
Name
Name/Position
Position
Shareholding
Change
Mr. Martijn Kleijwegt
Mr. Martijn Kleijwegt
Independent Director
Independent Director
470.97K
--
Mr. Pall Ragnar Johannesson
Mr. Pall Ragnar Johannesson
Chief Business Officer
Chief Business Officer
288.43K
+6.80%
Mr. Lionel Carnot
Mr. Lionel Carnot
Independent Director
Independent Director
90.75K
--
Ms. Sylvia Cheung, CPA
Ms. Sylvia Cheung, CPA
Chief Financial Officer
Chief Financial Officer
77.32K
+6.80%
Ms. Geraldine O'Keeffe
Ms. Geraldine O'Keeffe
Independent Director
Independent Director
20.59K
--
Ms. Christina M. Ackermann
Ms. Christina M. Ackermann
Independent Director
Independent Director
6.53K
--
Dr. Riad Sherif, M.D.
Dr. Riad Sherif, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Anthony A. (Tony) Rosenberg
Mr. Anthony A. (Tony) Rosenberg
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Arshad M. Khanani, M.D.
Mr. Arshad M. Khanani, M.D.
Independent Director
Independent Director
--
--
Mr. Robert K. Warner
Mr. Robert K. Warner
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Martijn Kleijwegt
Mr. Martijn Kleijwegt
Independent Director
Independent Director
470.97K
--
Mr. Pall Ragnar Johannesson
Mr. Pall Ragnar Johannesson
Chief Business Officer
Chief Business Officer
288.43K
+6.80%
Mr. Lionel Carnot
Mr. Lionel Carnot
Independent Director
Independent Director
90.75K
--
Ms. Sylvia Cheung, CPA
Ms. Sylvia Cheung, CPA
Chief Financial Officer
Chief Financial Officer
77.32K
+6.80%
Ms. Geraldine O'Keeffe
Ms. Geraldine O'Keeffe
Independent Director
Independent Director
20.59K
--
Ms. Christina M. Ackermann
Ms. Christina M. Ackermann
Independent Director
Independent Director
6.53K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, May 4
Updated: Mon, May 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
EQT Partners AB
11.51%
BVCF Management, Ltd.
4.04%
Gildi - lífeyrissjóður
4.02%
Pivotal Bioventure Partners Investment Advisor LLC
3.79%
abrdn Inc.
2.89%
Other
73.75%
Shareholders
Shareholders
Proportion
EQT Partners AB
11.51%
BVCF Management, Ltd.
4.04%
Gildi - lífeyrissjóður
4.02%
Pivotal Bioventure Partners Investment Advisor LLC
3.79%
abrdn Inc.
2.89%
Other
73.75%
Shareholder Types
Shareholders
Proportion
Private Equity
14.60%
Venture Capital
11.19%
Investment Advisor/Hedge Fund
6.74%
Pension Fund
5.13%
Individual Investor
4.27%
Investment Advisor
2.97%
Hedge Fund
2.71%
Research Firm
0.14%
Other
52.26%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
72
27.88M
54.68%
+2.54M
2025Q4
58
26.11M
45.16%
+9.73M
2025Q3
49
16.42M
28.41%
+792.94K
2025Q2
51
19.48M
37.42%
+1.76M
2025Q1
51
19.44M
37.35%
+1.93M
2024Q4
86
15.00M
31.97%
-10.87M
2024Q3
87
16.29M
41.43%
-9.17M
2024Q2
88
16.63M
42.28%
-9.14M
2024Q1
91
16.14M
42.22%
-11.25M
2023Q4
93
17.20M
46.87%
-6.97M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
EQT Partners AB
5.90M
11.57%
--
--
Dec 31, 2025
BVCF Management, Ltd.
2.19M
4.3%
+121.79K
+5.88%
Nov 27, 2024
Gildi - lífeyrissjóður
2.45M
4.8%
+2.45M
--
Dec 31, 2025
Pivotal Bioventure Partners Investment Advisor LLC
2.29M
4.49%
-12.12K
-0.53%
Dec 31, 2025
abrdn Inc.
1.75M
3.43%
+493.83K
+39.41%
Dec 31, 2025
Wellington Management Company, LLP
1.36M
2.66%
+842.51K
+164.02%
Dec 31, 2025
Sherif (Riad M.D.)
1.07M
2.09%
+421.53K
+65.38%
Dec 31, 2025
SR One Capital Management, LP
641.02K
1.26%
+318.52K
+98.77%
Dec 31, 2025
Saturn V Capital Management LP
516.76K
1.01%
+516.76K
--
Dec 31, 2025
Nan Fung Life Sciences
514.70K
1.01%
--
--
Dec 31, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Simplify Propel Opportunities ETF
2.81%
SPDR SSGA US Small Cap Low Volatility Index ETF
0.12%
Even Herd Long Short ETF
0%
Simplify Propel Opportunities ETF
Proportion2.81%
SPDR SSGA US Small Cap Low Volatility Index ETF
Proportion0.12%
Even Herd Long Short ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
